Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma - Wikidata - awgldk - TriplyDB

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

http://www.wikidata.org/entity/Q28297805

about

Interventions for mycosis fungoides Role of rituximab for first-line or relapsed aggressive B-cell lymphoma High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults Expression of topoisomerase IIIalpha in normal and neoplastic tissues determined by immunohistochemistry using a novel monoclonal antibody Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy Next-generation prognostic assessment for diffuse large B-cell lymphoma How I treat HIV-associated lymphoma Constitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell Lymphoma Treatment of diffuse large B cell lymphoma Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary Diffuse large B-cell lymphoma: current strategies and future directions Primary mediastinal B-cell lymphoma: treatment and therapeutic targets Pharmacokinetics and derivation of an anticancer dosing regimen for PAC-1, a preferential small molecule activator of procaspase-3, in healthy dogs Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP Network-based drug discovery by integrating systems biology and computational technologies A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature.Diagnosis and treatment of HIV-associated manifestations in otolaryngology Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris.Interpreting outcome data in hematological malignancies: a paradigm for clinical studies Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.Feasibility of ESHAP + G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients.Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group.Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas.Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: a single center experience.High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351.Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.

P2860

Q24200749-3CA17C1C-DB7E-44A8-B724-D9689C457375 Q24236580-FC164750-DB79-4AA7-BD69-1E6E4BB7667F Q24242089-EA3E70DD-F3C2-4F22-9E79-1CFBCD1D3133 Q24242447-9B6B952A-BD5D-47E1-A736-67C1A6C76435 Q24243100-EC7AB941-CF56-4C5E-B2E8-2ADDA5809D6B Q24250490-E3F02355-7321-4E8A-9736-124FD26FD932 Q24644151-64890DDE-69B6-49A7-AE72-43A38F765EE6 Q24646379-4B896C0D-F400-41D6-9073-2632FF5A4211 Q26782270-D0E23378-BF35-4381-AF69-B7424DECD1E3 Q26796428-07E56B0E-670F-41AB-B3D1-F695428598B4 Q26821860-F74ECC58-24F6-4296-B854-50EEC89742F9 Q26853170-1FD013D2-4F0B-4561-A2F3-169F108F8411 Q27006062-D1846D3F-B63B-4A8D-8E65-C5AE0DBC4F2C Q28088365-86E77B82-EC79-494C-BB91-5843CA0C6432 Q28269136-BAA791F9-2CD9-4B55-9A91-65948AC747E3 Q28278652-67519C49-1380-4073-9568-5C4F617A2A33 Q28283281-ABBB3F97-2C65-4256-BCCA-AED0E4AEA1CF Q28346778-0F9DA9B3-9F92-4C74-B6E3-D08A37A6BD78 Q28677268-0BD17293-6639-4538-AC4D-D2A218A4D661 Q30251621-DAF5B372-C9CA-4118-A654-AF33F87ADC36 Q30358406-47CFCA65-BF86-4A92-91C1-72400FC377FF Q30455450-7BAC4D48-41EF-493B-9638-237D3B4EF3CE Q30658847-990ECE3A-D4E0-42D6-8EA3-0270F99BA991 Q32083078-050A26B5-6C11-45E1-8627-22181014CFAD Q33217186-75A7FA9E-1FC1-49AC-A9E4-82226CCCB184 Q33328997-C1CF1420-FC69-4ADE-A244-D524CB88B8E6 Q33331027-A108BB67-1C4C-47AC-AA0B-F9F227A96B5A Q33338241-5242599A-211B-457A-BFFD-BB67CCD04B5C Q33340199-8558E535-4B0C-4E01-9A62-2490389B3CC1 Q33341146-3E2A75B6-B3FC-45EA-9DB5-9E6D3B900867 Q33344965-113CF9D9-03AB-471D-B879-A4E1DE9AD79A Q33349419-5E87FCFA-5996-4556-951F-D07CCEFC18E1 Q33364319-315C414E-690F-40A8-973E-92CEC69520E9 Q33367736-5F640FAD-18BD-473A-9B9E-1A906EDFF63F Q33372841-9215F9FE-8892-418E-BACA-7D81785D9378 Q33375173-3F31B0B0-E3B6-4CAE-A38B-AB9EAA83910E Q33379431-D3743669-683B-43DF-B5D4-9B0C354D39F3 Q33383571-6FD067D6-B32F-4665-862A-8442C291752E Q33389472-3D57DE0E-5A23-4FD9-AC46-8D7275ED78BA Q33396036-B3AE1933-E0AD-4FBF-ACE9-531A81857059

P2860

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

http://www.wikidata.org/entity/Q28297805

description

1993 nî lūn-bûn

@nan

1993 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1993 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

name

Comparison of a standard regim ...... dvanced non-Hodgkin's lymphoma

@ast

Comparison of a standard regim ...... dvanced non-Hodgkin's lymphoma

@en

Comparison of a standard regim ...... dvanced non-Hodgkin's lymphoma

@nl

type

label

Comparison of a standard regim ...... dvanced non-Hodgkin's lymphoma

@ast

Comparison of a standard regim ...... dvanced non-Hodgkin's lymphoma

@en

Comparison of a standard regim ...... dvanced non-Hodgkin's lymphoma

@nl

prefLabel

Comparison of a standard regim ...... dvanced non-Hodgkin's lymphoma

@ast

Comparison of a standard regim ...... dvanced non-Hodgkin's lymphoma

@en

Comparison of a standard regim ...... dvanced non-Hodgkin's lymphoma

@nl

P1433

Q28297805-288723FA-02A7-4BED-8785-8F0FD0B7662A

P1476

Q28297805-C22089CC-089F-4B71-B0AA-92C5C3FA5F61

P2093

Q28297805-1BC94A8E-72C3-4468-86B7-35C819470160

Q28297805-1E0D714F-D75C-44F4-A452-0F077F80A7E2

Q28297805-1F53EE60-7C15-4727-ADE0-9726F3BADFAC

Q28297805-2A53F4EE-B988-40BE-8BA4-AD8C03DB2907

Q28297805-2D252348-F1A5-4E04-90B7-DDEF4EF5D9FB

Q28297805-82BC2333-6214-439D-B2CE-0730CE6A465E

Q28297805-A53BA51A-24DB-4A20-93BE-1086089C14B0

Q28297805-AF820208-77A3-4955-89C2-B844F8C4483C

Q28297805-C3A2EA40-99AC-422F-8AEC-88C88610AEB6

P304

Q28297805-BD637BE3-D33D-4C38-86A1-BE100552A55F

P31

Q28297805-8A891187-ECB4-45F6-93E3-3FE1CBE80917

P3181

Q28297805-5598AE2A-FCBC-46E4-B5E7-3D5C2D63B3C6

P356

Q28297805-B2EA1D3A-8BD4-47FA-BB27-F7AE4B1310F4

P407

Q28297805-9B2980DA-5373-4631-A946-DD4FB0D06C3F

P433

Q28297805-2BD56BB3-FFFF-4670-A279-9C31F22AB784

P478

Q28297805-C5359929-D0CA-4444-A330-A67FE3757D6E

P577

Q28297805-BF436CF6-2E88-459C-92B4-96885C8F5DFB

P698

Q28297805-69939DA2-D4F0-47C7-9A26-CB4B8B24F208

Q28297805-ff673517-7461-45bd-90f7-655487acfb6b

P921

Q28297805-66AAD382-042A-4F6F-81C6-1E161406939E

P3181

P356

NEJM199304083281404

P1433

The New England Journal of Medicine

P1476

Comparison of a standard regim ...... dvanced non-Hodgkin's lymphoma

@en

P2093

C A Coltman

http://www.w3.org/2001/XMLSchema#string

E M Mize

http://www.w3.org/2001/XMLSchema#string

E R Gaynor

http://www.w3.org/2001/XMLSchema#string

J H Glick

http://www.w3.org/2001/XMLSchema#string

M M Oken

http://www.w3.org/2001/XMLSchema#string

R I Fisher

http://www.w3.org/2001/XMLSchema#string

S Dahlberg

http://www.w3.org/2001/XMLSchema#string

T M Grogan

http://www.w3.org/2001/XMLSchema#string

T P Miller

http://www.w3.org/2001/XMLSchema#string

P304

1002-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1315368

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJM199304083281404

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

328

http://www.w3.org/2001/XMLSchema#string

P577

1993-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7680764

http://www.w3.org/2001/XMLSchema#string

P921